Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Phase 2 Study of Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

The goal of this study is to access whether treatment of early state estrogen-rich breast cancers with neoadjuvant endocrine therapy will result in higher rates of margin negativity on lumpectomy specimen.

Inclusion Criteria:

• Pathologically confirmed invasive breast cancer, clinically stage I-II.
• Clinically lymph node negative
• Eligible for anti-endocrine treatment (per medical oncologist)
• Postmenopausal women
• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Progesterone receptor negativity
• High grade tumor
• Synchronous non-breast malignancy
• Receiving any other investigational agents that could impact the efficacy of this trial regimen
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to Anastrozole, Letrozole, Exemestane, Tamoxifen or other agents used in study
• Uncontrolled intercurrent illness
• Medical, psychiatric or other condition and/or social situations that would limit compliance with study requirements